IO Biotech Inc
IOBT0.350USD
+0.030+9.27%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
24.39MCap. mercado
PérdidaP/E TTM
Más Datos de IO Biotech Inc Compañía
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Información de IO Biotech Inc
Símbolo de cotizaciónIOBT
Nombre de la empresaIO Biotech Inc
Fecha de salida a bolsaNov 05, 2021
Director ejecutivoZocca (Mai-Britt)
Número de empleados80
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 05
DirecciónOle Maaloes Veh 3
CiudadCOPENHAGEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísDenmark
Código postal2200
Teléfono4570702980
Sitio Webhttps://www.iobiotech.com/
Símbolo de cotizaciónIOBT
Fecha de salida a bolsaNov 05, 2021
Director ejecutivoZocca (Mai-Britt)
Ejecutivos de IO Biotech Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+12000.00%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
+15000.00%
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
--
--
Ms. Amy B. Sullivan
Ms. Amy B. Sullivan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Qasim Ahmad, M.D.
Dr. Qasim Ahmad, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+12000.00%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
+15000.00%
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 1 de feb
Actualizado: dom., 1 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Ikarian Capital LLC
2.12%
Otro
58.69%
Accionistas
Accionistas
Proporción
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Ikarian Capital LLC
2.12%
Otro
58.69%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
29.12%
Investment Advisor
6.63%
Hedge Fund
5.28%
Individual Investor
5.14%
Investment Advisor/Hedge Fund
2.37%
Research Firm
1.26%
Otro
50.20%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
52
34.65M
48.27%
-16.00M
2025Q3
49
42.06M
63.84%
-13.38M
2025Q2
52
43.99M
66.77%
-12.21M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
2023Q3
56
56.33M
89.04%
+20.70M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Lundbeckfond Ventures
13.95M
19.39%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
9.48%
--
--
Apr 11, 2025
HBM Partners AG
3.94M
5.48%
--
--
Apr 11, 2025
Chernett (Jorey)
3.48M
4.83%
+3.48M
--
Oct 30, 2025
Ikarian Capital LLC
1.53M
2.12%
+1.53M
--
Sep 30, 2025
Millennium Management LLC
1.39M
1.94%
+1.39M
--
Sep 30, 2025
Marshall Wace LLP
1.05M
1.46%
-1.05M
-50.00%
Sep 30, 2025
BofA Global Research (US)
799.95K
1.11%
-815.12K
-50.47%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
668.40K
0.93%
+14.72K
+2.25%
Sep 30, 2025
Boothbay Fund Management, LLC
591.18K
0.82%
+591.18K
--
Sep 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
